Adaptive Biotechnologies Corp (NASDAQ: ADPT) is a leading biotechnology company focusing on immune-driven medicine.Julie Rubinstein, President and COO, executed a series of stock sales in March 2026, significantly reducing her holdings.Despite challenges in profitability, ADPT shows financial stability with a strong current ratio and a moderate level of debt.Adaptive Biotechnologies Corp (NASDAQ: ADPT) is a biotechnology company that focuses on the development of immune-driven medicine. The company leverage ...

Core Insights - Adaptive Biotechnologies' stock experienced a 5.8% increase, closing at $13.17, following a significant trading volume, contrasting with a 19.9% decline over the past month [1] - The positive investor sentiment is driven by the potential of the company's pipeline, particularly its lead product clonoSEQ, which monitors minimal residual disease in hematologic cancers [2] - The company is advancing its Immune Medicine platform to discover T-cell receptor-based therapeutics for various diseases, alongside research programs aimed at identifying disease-specific immune responses [2] Financial Expectations - The company is projected to report a quarterly loss of $0.16 per share, reflecting a year-over-year increase of 20%, with expected revenues of $61.84 million, up 17.9% from the previous year [3] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Adaptive Biotechnologies holds a Zacks Rank of 3 (Hold) within the Medical - Biomedical and Genetics industry, which includes other companies like AnaptysBio, Inc. [5] - AnaptysBio's EPS estimate has seen a significant revision of +34.5% over the past month, indicating a change of +43.8% from the previous year, also holding a Zacks Rank of 3 (Hold) [6]

Summary of Adaptive Biotechnologies FY Conference Call Company Overview - **Company**: Adaptive Biotechnologies (NasdaqGS:ADPT) - **Industry**: Life Sciences, specifically focusing on diagnostics and immune medicine Key Points and Arguments 1. Strong Performance in 2025 - The company reported accelerated volume growth, multiple guideline inclusions, and improvements in average selling price (ASP) for its clinical business in 2025, setting a positive outlook for 2026 [4][3] 2. Growth Expectations for 2026 - The company anticipates greater than 30% ClonoSEQ volume growth for 2026, building on the successful strategies implemented in the previous year [5][8] - Five key growth drivers identified: blood-based testing, community presence, guideline inclusion, increased data generation, and EMR integration [5][4] 3. Community vs. Academic Testing - Testing distribution at the end of the previous year was 33% community and 67% academic, with expectations to reach 35% community by the end of 2026 [11][12] - Community testing is growing at approximately 14%, while academic testing is growing at about 8-9% [11][12] 4. EMR Integration and Repeat Testing - EMR integration has significantly improved the ease of ordering tests, with 75% of doctors utilizing repeat ordering functions [13][14] - Compliance rates for repeat testing are around 63-65% [14] 5. Guideline Inclusions and Their Impact - The company has achieved five guideline inclusions across various indications, with a typical lag of 6-9 months before these changes impact ordering patterns [17][18] 6. Clinical Trials and Potential Updates - Upcoming interim readouts from trials such as MASTER-2 and BOVen could lead to practice-changing updates in guidelines for multiple myeloma and CLL [19][24] 7. Pricing Strategy - The ASP increased from $1,117 to $1,307 (17% increase) last year, with a projected increase to $1,400 (7% increase) this year [36][37] - Factors contributing to price increases include new payer contracts and improved revenue cycle management [38][39] 8. Competitive Landscape - The company positions ClonoSEQ as the gold standard in hematological MRD testing, emphasizing its specificity and sensitivity compared to competitors like Natera [72][74] - The market for DLBCL is under-penetrated, with only 3% penetration, presenting an opportunity for growth [75] 9. International Expansion Plans - The company is pursuing a capital-efficient technology transfer model for international markets, with successful implementations in several countries [64][66] 10. Financial Outlook - The company aims for gross margins of 75-80% and operating margins of 20-25% as it scales operations [87][88] - The MRD business is expected to continue its growth trajectory, with significant potential in the immune medicine sector as well [91][92] Additional Important Insights - The company is focused on enhancing market access and reimbursement policies, particularly for recurrence monitoring and expanding test bundles [57][62] - The immune medicine business is viewed as a significant growth opportunity, with ongoing investments in data generation [91][92] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Adaptive Biotechnologies' growth potential and competitive positioning in the life sciences industry.

Core Insights - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is recognized as a promising stock under $20 following its fiscal Q4 and full-year 2025 earnings release on February 5 [1] Group 1: Earnings and Ratings Updates - TD Cowen raised the price target for ADPT to $21 from $20 while maintaining a Buy rating after the fiscal Q4 earnings beat, citing positive signals from various drivers such as the shift to blood-based tests and EMR integrations [2] - BTIG also increased the price target for ADPT to $22 from $21, keeping a Buy rating, and noted that the company is performing strongly in the specialty labs sector [3] - JPMorgan updated its rating for ADPT, raising the price target to $21 from $20 and maintaining an Overweight rating [3] Group 2: Company Overview - Adaptive Biotechnologies Corporation is focused on developing an immune medicine platform, offering services and products like immunoSEQ, clonoSEQ, cellular therapy, and vaccines [4]

Financial Performance - In 2025, the company's revenue reached $277.0 million, a 55% increase from $179.0 million in 2024, primarily driven by the MRD business which grew by $66.8 million[21]. - The company reduced net cash used in operations to $46.0 million in 2025, a 52% decrease from $95.2 million in 2024[21]. - For the year ended December 31, 2025, the company incurred a net loss of $59.5 million, compared to $159.6 million in 2024 and $225.3 million in 2023, with an accumulated deficit of $1.4 billion as of December 31, 2025[161]. - The Revenue Interest Purchase Agreement with OrbiMed provided the company with $124.4 million, with a revenue interest payment of 5% of quarterly GAAP revenue[65][66]. Market and Product Development - The total addressable market for the MRD business is approximately $6.2 billion, with about $5.3 billion derived from clinical testing[17]. - The total MRD revenue in 2025 was $212.3 million, representing a 46% growth from 2024, with clonoSEQ test volume increasing to 105,587 tests delivered, a 39% year-over-year increase[22]. - The company is attempting to generate sufficient clinical evidence to support the utility of MRD in additional lymphoid cancers beyond ALL, MM, CLL, DLBCL, and MCL[168]. - The company expects to make significant investments in research and development of new products and services, which may not be successful[171]. Regulatory and Compliance - The company is subject to various federal and state regulations, including CLIA certification, to ensure compliance in laboratory testing and operations[108]. - The company must adhere to HIPAA and HITECH regulations for the protection of personal health information, ensuring compliance with privacy and security standards[118]. - The company is regulated under the Federal Trade Commission Act (FTCA), which requires reasonable data security measures to protect consumer information[121]. - The company must comply with varying regulatory requirements in international markets, which could delay the introduction of its products[206]. Intellectual Property and Technology - The company holds 416 issued and allowed patents and 64 pending patent applications as of December 31, 2025, covering various aspects of its technology[75][78]. - The company has developed methods for predicting responses to immunotherapy, with extensive patent protection including U.S. Patent No. 10,221,461[89]. - The company acquired an exclusive paid-up license for patents related to the diagnosis and monitoring of proliferative disorders, covering regions including the U.S., Europe, Australia, and China[92]. - The company has operationalized the NovaSeq X Plus sequencers for clonoSEQ clinical testing, transitioning all MRD testing to this system over the next two years[71]. Competitive Landscape - The company faces intense competition in the biotechnology and pharmaceutical industries, particularly in immune medicine, with competitors having greater financial resources and expertise[99]. - The company faces significant competition in the biotechnology and pharmaceutical industries, particularly in immune medicine, which is characterized by rapidly advancing technologies[201]. - Certain large private payors have issued non-coverage policies for testing methods deemed experimental, which could adversely affect demand for the company's tests[165]. Employee and Organizational Structure - The company has a total of 624 full-time employees as of December 31, 2025, with 94 holding medical or doctoral degrees[153]. - The company has been recognized as one of Washington State's Best Places to Work from 2018 to 2022 and received national certification as a Great Place to Work in 2021 and 2022[154]. - The company relies on the skills and experience of its senior management team, and any loss of key members could adversely affect operations[209]. Clinical and Diagnostic Advancements - The clonoSEQ assay has been used in over 180 active trials by more than 40 biopharmaceutical partners, with over 100 trials using MRD as a clinical endpoint[30]. - The clonoSEQ test is the first FDA-authorized test for detecting and monitoring MRD in multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia[18]. - The Phase 3 MajesTEC-3 study showed MRD negativity rates of 58.4% for teclistimab-daratumumab compared to 17.1% for the control group, correlating with improved progression-free survival[48]. Financial and Market Risks - The company anticipates continued proposals from legislators and regulators that could impact the demand for its products and services, potentially expanding or contracting the insured population[145]. - The company may experience unforeseen events during clinical trials that could delay or prevent regulatory clearance and commercialization of its products[186]. - The company may not achieve significant commercial market acceptance for its products due to potential undesirable side effects and varying interpretations of clinical data[196].

Core Viewpoint - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is experiencing positive momentum with multiple analysts upgrading their price targets following a strong Q4 earnings report, highlighting its growth potential in the specialty labs sector. Group 1: Analyst Upgrades - TD Cowen upgraded the price target for Adaptive Biotechnologies from $20 to $21 while maintaining a Buy rating, citing factors such as community adoption and a shift to blood-based testing as key drivers [1] - BTIG maintained a Buy rating and increased the price target from $21 to $22, describing the company as a leading growth story in specialty labs [2] - JPMorgan raised the price objective from $20 to $21 while retaining an Overweight rating, noting strong Q4 results and projecting FY26 MRD business revenue between $255 million and $265 million [3] Group 2: Company Overview - Adaptive Biotechnologies develops an immune medicine platform, offering products such as immunoSEQ, clonoSEQ, cellular treatment, and vaccinations [5]

Core Insights - Adaptive Biotechnologies reported a quarterly loss of $0.09 per share, outperforming the Zacks Consensus Estimate of a loss of $0.19, and showing improvement from a loss of $0.23 per share a year ago, resulting in an earnings surprise of +52.63% [1] - The company achieved revenues of $71.68 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.44%, but represented a significant increase from $47.46 million in the same quarter last year [2] - The stock has gained approximately 6.5% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] Earnings Outlook - The earnings outlook for Adaptive Biotechnologies is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.17 on revenues of $61.01 million, and for the current fiscal year at -$0.59 on revenues of $266.15 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adaptive Biotechnologies belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Guardant Health, is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year change of +32.3%, with revenues anticipated to be $279.96 million, up 38.7% from the previous year [9][10]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [20][21] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [21][22] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [22] Business Line Data and Key Metrics Changes - In the MRD business, full-year revenue grew 46% year-over-year, with clinical testing revenue increasing 64% for the full year and 59% in Q4 [5][8] - clonoSEQ test volume reached 30,038 tests in Q4, up 43% year-over-year, with blood-based testing accounting for 47% of tests, an increase from 41% a year ago [8][9] - Immune medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [23] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for roughly 70% of sequencing revenue [12] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to reach an average of $1,400 per test in 2026 [10][11] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [14][27] - In immune medicine, the strategy includes advancing TCR antigen datasets and AI/ML modeling work, with a target net cash burn of $15-$20 million [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong sequential growth in Q1 2026 despite potential weather-related impacts on sample arrival [32] - The company anticipates clonoSEQ test volumes to grow by more than 30% year-over-year in 2026, supported by a shift towards blood-based testing and deeper community penetration [15][16] Other Important Information - The company ended the year with a strong cash balance of $227 million, excluding cash held by digital biotechnologies [24] - The MRD business is expected to generate between $255-$265 million in revenue for 2026, with a focus on maintaining disciplined spending and achieving positive adjusted EBITDA [25][26] Q&A Session Summary Question: Discussion on clonoSEQ volume trends and seasonality - Management noted that Q4 results indicate strong growth and that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in their guidance for the year [30][32] Question: Penetration rates in DLBCL and competition - Management highlighted that while DLBCL penetration is currently low, they are focusing on data generation, guideline advancements, and deepening pharma relationships to drive growth [34][36] Question: Competitor's flow cytometry assay and pricing - Management emphasized that their clonoSEQ assay is more sensitive than competitors' offerings, which positions them favorably in the market [41][43] Question: ASP pacing and payer negotiations - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers that could impact overall pricing [44][60] Question: EBITDA guidance for 2026 - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD business already positive [48][49] Question: Community and blood-based testing growth assumptions - Management expressed confidence in the potential for further growth in both community and blood-based testing, with ongoing investments to drive these areas [50][52] Question: Monetization of immune medicine data - Management discussed the potential for additional data licensing deals and the value of their proprietary dataset in immunology applications [74][75]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [20][21] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [21][22] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [22] Business Line Data and Key Metrics Changes - In the MRD business, full-year revenue grew 46% year-over-year, with clinical testing revenue increasing 64% for the full year and 59% in Q4 [5][8] - clonoSEQ test volume reached 30,038 tests in Q4, up 43% year-over-year, with blood-based testing accounting for 47% of total tests [8][9] - Immune Medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [22][23] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for roughly 70% of sequencing revenue [12] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to reach approximately $1,400 per test in 2026 [10][11] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [14][27] - In 2026, the company expects clonoSEQ test volumes to grow by more than 30% year-over-year, with a significant shift towards blood-based testing [15][16] - The Immune Medicine business is focusing on generating large-scale proprietary immune receptor data and monetizing this data through partnerships [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA and free cash flow by the end of 2026, with a focus on disciplined spending and operational efficiency [26] - The company is optimistic about the momentum in MRD and the potential for continued growth in the Immune Medicine sector [27] Other Important Information - The company ended the year with a strong cash position of $227 million, providing flexibility for future investments [22][24] - The company plans to maintain a disciplined capital allocation strategy, with a target net cash burn of $15 million to $20 million for the Immune Medicine business in 2026 [19] Q&A Session Summary Question: Discussion on clonoSEQ volume trends and seasonality - Management acknowledged Q4's strong results and noted that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in achieving strong sequential growth in Q1 [30][32] Question: Penetration rates in DLBCL and competition - Management highlighted the importance of data generation, guideline advancements, and deepening penetration with pharma to increase market share in DLBCL, where current penetration is low [34][36] Question: Competitive flow cytometry assay and pricing - Management emphasized that flow-based methods are inherently less sensitive than clonoSEQ, which maintains a significant advantage in sensitivity for myeloma testing [40][42] Question: ASP pacing and payer negotiations - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers that could impact ASP realization [43][44] Question: EBITDA guidance for 2026 - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD expected to contribute positively [46][47] Question: Community and blood-based testing growth assumptions - Management expressed confidence in the potential for further growth in blood-based testing and community penetration, with ongoing investments to drive these areas [50][51] Question: Monetization of the Immune Medicine data - Management discussed the potential for additional data licensing deals and the value of their proprietary dataset in various immunology applications [72][73]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [19][20] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [19][20] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [20] Business Line Data and Key Metrics Changes - In the MRD business, revenue grew 54% year-over-year in Q4, with clinical and pharma contributions of 67% and 33%, respectively [20] - clonoSEQ test volume increased by 43% year-over-year, reaching 30,038 tests in Q4 [20] - Immune medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [21] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for approximately 70% of sequencing revenue [11] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to increase it to approximately $1,400 per test in 2026 [10][24] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [12][15] - In immune medicine, the strategy includes advancing TCR antigen datasets and AI/ML modeling work, with a target net cash burn of $15-$20 million [18] - The company plans to leverage its large-scale proprietary data for monetization through licensing deals, particularly in immunology applications [17][75] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong sequential growth in Q1 2026 despite potential weather-related impacts on sample arrival [31] - The company anticipates continued growth in clonoSEQ test volumes, with expectations of over 30% year-over-year growth supported by blood-based testing and deeper community penetration [13][14] - Management highlighted the importance of maintaining a strong cash position, ending 2025 with $227 million in cash, cash equivalents, and marketable securities [23] Other Important Information - The company achieved a 68% reduction in cash burn, indicating improved operational efficiency [6] - The MRD business is expected to generate between $255-$265 million in revenue for 2026, with a focus on expanding market presence and leveraging existing infrastructure [24] Q&A Session Summary Question: Can you discuss the sequential step up in clonoSEQ volume and any seasonality? - Management noted that Q4 results demonstrated strong growth and that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in achieving strong growth in Q1 [30][31] Question: How should we think about penetration rates in DLBCL? - Management indicated that they are applying lessons learned from multiple myeloma to increase penetration in DLBCL, focusing on data generation and expanding commercial payer coverage [32][34] Question: Thoughts on a competitor's flow cytometry assay? - Management emphasized that flow-based methods are inherently less sensitive than clonoSEQ, which maintains a significant advantage in sensitivity for MRD assessment [40][42] Question: Can you elaborate on the EBITDA guidance for 2026? - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD already contributing positively [46][48] Question: What are the expectations for ASP growth in 2026? - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers influencing the final rates [58][60]